Status:

COMPLETED

The Effect of Fasudil on Vascular Function in Humans

Lead Sponsor:

Brigham and Women's Hospital

Conditions:

Atherosclerosis

Hypercholesterolemia

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The purpose of the study is to evaluate how the rho kinase inhibitor, fasudil, affects vascular function in patients with atherosclerosis and hyperlipidemia.

Eligibility Criteria

Inclusion

  • Coronary artery disease
  • Hyperlipidemia -OR-
  • Healthy adults

Exclusion

  • Unstable angina, myocardial infarction or revascularization within 3 months
  • Symptomatic heart failure
  • Creatinine \> 3.0 mg/dl
  • Liver enzymes \> 3X upper limit of normal
  • Chronic hypoxia
  • Significant anemia
  • Chronic inflammatory disease
  • Pregnancy
  • Willing to withdraw statins for duration of study

Key Trial Info

Start Date :

June 1 2002

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

January 1 2007

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT00120718

Start Date

June 1 2002

End Date

January 1 2007

Last Update

September 30 2008

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Brigham and Women's Hospital

Boston, Massachusetts, United States, 02115